Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Healios reported that last patient in its Phase 2/3 TREASURE study, evaluating MultiStem, a patented regenerative medicine product for the treatment of ischemic stroke, completed the 365-day follow-up visit.
Lead Product(s): Invimestrocel
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MultiStem
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Athersys
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
This agreement will enable both Athersys and Healios to focus on advancing their late-stage programs for MultiStem, including preparing for top line results from Healios’ TREASURE trial for stroke and ONE-BRIDGE trial for ARDS, which is expected this year.
Lead Product(s): MultiStem
Therapeutic Area: Neurology Product Name: HLCM051
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Athersys
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 16, 2021
Details:
HEALIOS K.K continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051.
Lead Product(s): HLCM051
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Details:
The SSC candidate of Healios (HLCM051) is in an ischemic stroke pivotal phase 2/3 trial in Japan in which it offers the potential to provide effective treatment over a much longer treatment window.
Lead Product(s): HLCM051
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2020